GOLDMAN SACHS GROUP INC (GS) Stock News

Vanguard's VCSH and iShares' IGSB are nearly identical short-term corporate bond ETFs targeting investment-grade debt maturing within five years. VCSH has a slightly lower expense ratio (0.03% vs 0.04%) and larger assets under management, while IGSB offers more holdings (4,706 vs 3,030) and a marginally higher dividend yield (4.6% vs 4.5%). Both are solid choices with comparable performance and risk profiles.

GSK's Specialty Medicines segment, accounting for over 40% of sales, grew 14% in H1 2026 driven by HIV, respiratory, and oncology products. The company is accelerating R&D with over 20 phase III starts planned for 2026. However, GSK faces a significant challenge as dolutegravir patents expire in 2028-2029, threatening its HIV franchise which generated £2.74 billion in H1 2026. GSK is relying on long-acting HIV injectables and next-generation pipeline products to offset future generic competition.

Zachry Construction Corporation has been awarded contracts to deliver airfield infrastructure improvements at Greenville-Spartanburg International Airport (GSP) in South Carolina and Raleigh-Durham International Airport (RDU) in North Carolina. The projects include taxilane widening, apron reconstruction, pavement rehabilitation, and airfield lighting to support capacity expansion and operational efficiency at both growing Southeast aviation hubs.

Rosen Law Firm is notifying investors in Taboola.com Ltd. who purchased securities between May 6, 2026 and August 4, 2026 of an important October 20, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Taboola.com made materially false and misleading statements regarding an increase in low-quality publishers, the need for aggressive publisher relationship exits, and overstated publisher relationship values, which impacted earnings and investor returns.

Goldman Sachs (GS) has been highlighted as a strong investment opportunity due to positive earnings growth and price momentum. The company, added to the Zacks Focus List in July 2018, has seen shares increase 357.84% since then. Seven analysts revised earnings estimates higher in the last 60 days, with the consensus estimate increasing to $68.89, and GS is rated #1 (Strong Buy) on the Zacks Rank with expected earnings growth of 34.2% for the current fiscal year.

Rosen Law Firm alerts PROCEPT BioRobotics investors with losses exceeding $100K about a September 22, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges PROCEPT made materially false statements regarding undisclosed discount programs that artificially inflated handpiece unit sales and revenues, created excess field inventory exceeding 10,000 units, and rendered 2025 guidance unachievable.

The WisdomTree Emerging Markets SmallCap Dividend ETF (DGS) has $1.77 billion in assets and offers 3.72% dividend yield with a 0.58% expense ratio. While it has performed well with 15.3% gains year-to-date and 18.93% over the past year, the article suggests it is not suitable for investors seeking to outperform the broad emerging markets segment. Cheaper alternatives like VWO and IEMG are recommended for investors seeking lower costs and reduced risk.

Moderna secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine, establishing a foothold in the multibillion-dollar flu vaccine market. However, GSK announced plans to advance its own mRNA flu vaccine into phase III trials, which targets two viral proteins (HA and NA) and showed superior immune responses in phase II studies. While GSK's vaccine is still years away from market approval, it could pose a competitive challenge to Moderna's mFlusiva, which currently targets only HA like traditional flu vaccines.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against The Simply Good Foods Company (SMPL) for allegedly making false statements regarding its OWYN acquisition. The lawsuit claims the company failed to disclose operational failures, product quality issues, margin erosion, and failed integration of the acquired assets. The lead plaintiff deadline is October 13, 2026.

GSI Technology announced that Vice President of Sales and Investor Relations Didier Lasserre will present at the Nasdaq/LD Micro Summit Series on September 9, 2026, in San Francisco. The company will deliver a 15-minute overview followed by a Q&A breakout session to institutional investors.

Teucrium Agricultural ETF (TAGS) has reached a 52-week high, rising 25.7% from its low, driven by severe weather disruptions in key growing regions, geopolitical risks in export hubs, and rising global demand. The fund, which tracks corn, wheat, soybeans, and sugar, shows positive momentum with a weighted alpha of 26.59, suggesting potential for continued gains in the near term.

Rosen Law Firm is reminding investors who purchased HDFC Bank Limited (NYSE: HDB) securities between July 17, 2023 and May 26, 2026 of an October 13, 2026 deadline to join a class action lawsuit. The lawsuit alleges that HDFC Bank made materially false statements by camouflaging payments as marketing spend to pay higher interest to a state firm, activities allegedly approved by senior management that likely violated regulations and overstated interest income and operating expenses.

Rosen Law Firm is reminding investors in Aardvark Therapeutics, Inc. of an October 13, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aardvark made materially false and misleading statements regarding the safety and prospects of its drug ARD-101, and failed to disclose material adverse facts about the company's business and operations.

A securities class action lawsuit has been filed against Capricor Therapeutics for allegedly making materially false statements regarding its Deramiocel cell therapy. The lawsuit claims the company made undisclosed changes to statistical analysis plans for clinical data and failed to obtain FDA agreement before resubmitting the Biologics License Application, creating substantial regulatory approval risks. Investors who purchased securities between December 17, 2025 and July 26, 2026 may be eligible for compensation, with a lead plaintiff deadline of September 28, 2026.

GSLC is a passively managed large-cap blend ETF with $15.28 billion in assets and a very low expense ratio of 0.09%. The fund has delivered 11.79% year-to-date returns and 17.05% over the past year, with significant exposure to technology stocks including Nvidia, Apple, and Microsoft. It carries a Zacks ETF Rank of 3 (Hold), positioning it as a sufficient but not exceptional option compared to competitors like VOO and IVV.

Rosen Law Firm announced multiple securities class action lawsuits with upcoming deadlines. The primary case involves Wix.com Ltd., where investors who purchased securities between February 19, 2025 and May 12, 2026 may be eligible for compensation. The lawsuit alleges Wix made false statements about its AI product offerings, overstating competitiveness and performance while understating development costs. The lead plaintiff deadline is September 22, 2026. Similar class actions were also filed against Microvast Holdings, Inc. and Photronics, Inc.

Zacks presents its Focus List, a curated portfolio of 50 stocks selected based on earnings estimate revisions and the proprietary Zacks Rank system. The methodology relies on upward earnings revisions as a predictor of future stock performance. Historical data shows the Focus List returned 2,519.23% cumulatively since February 1996, outperforming the S&P 500's 854.95% return. Goldman Sachs is highlighted as a Focus List example, having gained 358.66% since its July 2018 addition.

The Roundhill Magnificent Seven ETF (MAGS) has underperformed major indexes year-to-date, up only 2% compared to the S&P 500 and Nasdaq's 12% gains. Despite this, investors remain interested due to five of the seven megacap stocks trading at below-average valuations. The concentrated portfolio carries higher volatility risk but offers potential for outperformance when markets rally.

GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy  Reuters

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Cogent Communications Holdings, Inc. (CCOI) on behalf of investors who purchased stock between February 29, 2024 and May 1, 2026. The lawsuit alleges that defendants made materially false statements regarding optical wavelength backlog orders, customer demand, revenue targets, dividend sustainability, and undisclosed risks related to insider stock pledging activities. The lead plaintiff deadline is September 21, 2026.

A class action lawsuit has been filed against BitGo Holdings, Inc. (NYSE: BTGO) alleging that the company's IPO offering documents were negligently prepared and contained false or misleading statements. The lawsuit claims BitGo understated risks related to declining digital asset prices and lacked a reasonable basis for statements about its financial performance and business prospects. Investors who purchased BitGo securities between January 22, 2025 and May 13, 2026 have until August 7, 2026 to apply to be appointed as lead plaintiff.

Rosen Law Firm has filed a class action lawsuit against Pentwater Capital Management LP and its CEO Matthew Halbower, alleging they orchestrated a market manipulation scheme involving Avis Budget Group securities. The defendants allegedly used their position as a major shareholder (holding ~51% economic interest) to aggressively purchase Avis stock during February 2025 to April 2026, triggering a short squeeze and artificial price volatility that benefited their holdings. Investors who purchased Avis securities during this period may be eligible for compensation.

Rosen Law Firm is reminding investors who purchased Primoris Services Corporation stock between August 5, 2025 and June 22, 2026 of the September 21, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Primoris made false statements regarding its cost estimation processes and project oversight for fixed-price renewable energy projects, which led to systematic underestimation of costs and risks, resulting in material cost overruns and execution problems.

A class action lawsuit has been filed against BitGo Holdings, Inc. alleging that the company made false and misleading statements in its January 2026 IPO offering documents. The lawsuit claims BitGo understated risks related to declining digital asset prices and lacked a reasonable basis for statements about its financial performance and business prospects. Investors who purchased BitGo securities between January 22, 2025 and May 13, 2026 have until August 7, 2026 to apply as lead plaintiff.

Rosen Law Firm is notifying investors in First Solar, PicS N.V., and Erasca of upcoming lead plaintiff deadlines in securities class action lawsuits. First Solar faces allegations of making false statements regarding tariff policy management and production facility impacts. The firm is encouraging investors who purchased securities during specified class periods to seek legal counsel.

A securities class action lawsuit has been filed against GeneDx Holdings Corp. (WGS) for allegedly making false statements about the Fabric acquisition's impact on the company's financials and operational efficiencies. The lawsuit claims defendants knew of significant problems with Fabric's viability that would negatively impact the business. Investors with losses exceeding $100K are encouraged to join the class action before the August 3, 2026 lead plaintiff deadline.

Rosen Law Firm announces a securities class action lawsuit against GeneDx Holdings Corp (WGS) for alleged false statements regarding the Fabric acquisition. The firm claims GeneDx made misleading statements about cost reduction and operational synergies that never materialized, causing investor losses. The deadline to join the class action is August 3, 2026.

GeneDx Holdings Corp. (WGS) investors with substantial losses have until August 3, 2026 to seek appointment as lead plaintiff in a securities fraud class action lawsuit. The lawsuit alleges that GeneDx made false and misleading statements regarding the viability of its Fabric Genomics acquisition. GeneDx's stock dropped over 49% on May 4, 2026 after revealing a significant drop in adjusted gross margin from 74% to 69%, reduced earnings projections, and a $31.3 million impairment loss directly attributable to Fabric Genomics.

Rosen Law Firm announces a securities class action lawsuit against PicS N.V. (NASDAQ: PICS) regarding alleged false and misleading statements in its January 2026 IPO offering documents. The lawsuit claims PicS failed to disclose deficient credit evaluation procedures, material reclassifications of credit exposures, undisclosed heightened default rates, and deteriorating customer credit quality. The lead plaintiff deadline is August 4, 2026.

A class action lawsuit has been filed against BitGo Holdings, Inc. alleging that the company's IPO offering documents were negligently prepared and contained false or misleading statements. The lawsuit claims BitGo understated risks related to declining digital asset prices and lacked a reasonable basis for statements about its financial performance and business prospects. Investors who purchased BitGo securities between January 22, 2025 and May 13, 2026 have until August 7, 2026 to apply as lead plaintiff.